For the detection of neutralizing antibodies of SARS-CoV-2, sELISA kits offer a convenient alternative to neutralization tests, as they can be used under standard laboratory safety conditions. A recent study compared two commercially available kits and tested their specificity and selectivity.
The recent and rapid spread of the novel coronavirus, SARS-CoV-2, has necessitated the development of new assays that are capable of detecting the presence of this virus in patient samples or evidence of recent infection.
AAT Bioquest offers a variety of dark-FRET peptide substrates and fluorogenic substrates which can be effectively used to screen for inhibitors of coronavirus proteases, papain-like proteases and more.
In the current state of the COVID-19 pandemic, there is high demand for rapid tests using a lateral flow technique for the detection of IgG and IgM antibodies against SARS-CoV-2.
Currently, there are no approved drugs to treat the SARS-CoV-2 infection that causes COVID-19. Existing drugs are being examined for strategies to treat the disease.
We are pleased to introduce a new kit from Assay Genie for robust and reproducible one-step coronavirus detection using real time RT-qPCR.
The novel coronavirus SARS-CoV-2, which causes COVID-19, shares 79.5% sequence identity with the virus responsible for SARS. Both viruses use the same receptor ACE2 for mediating viral entry into host cells.